Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Neuropharmacology ; 79: 616-25, 2014 Apr.
Article in English | MEDLINE | ID: mdl-24462620

ABSTRACT

A subgroup of anticonvulsant and neuroleptic drugs acts through the potentiation of GABA pathways. The regulatory role of GABA in neuronal circuit formation is related to its depolarizing action that supports activity-dependent synaptogenesis. We hypothesized that elevated levels of GABA in the immature brain modify synaptogenesis in excitatory synapses and consequently affect mice behavior. In support of this theory, we showed previously that neonatal exposure to a GABA-transaminase inhibitor (Vigabatrin, GVG) modifies the expression of presynaptic proteins and suppresses excitatory synaptic potentials. To further characterize this phenomenon, we examined the effect of GVG applied during postnatal days 4-14, during the switch in GABA function from a depolarizing to a hyperpolarizing substance, on the development of excitatory synapses and mice sociability. Early exposure to GVG induced differential effects on synaptic proteins in the hippocampus and the cerebral cortex, including the downregulation of GluR1/GluR2 and NR2A/NR2B ratios in the hippocampus cytoplasm, a minute effect on the regulatory proteins CAMKII and PKA in the cerebral cortex, and increases in pGluR1, CAMKII, PKA and Reelin levels. Early GVG exposure was also associated with region specific regulation of monoamines, reduction in hippocampal DA, and enhancement of cortical NE levels. Age-dependent modified sociability and lack of preference for social interactions were observed in mice treated with GVG. Overall, early life exposure to GVG is expected to alter cortico-hippocampal axis connectivity and balance due to the different effects GVG has on key synaptic proteins in the associated brain regions, thus potentially causing behavioral impairment.


Subject(s)
Cerebral Cortex/growth & development , Cerebral Cortex/metabolism , Hippocampus/growth & development , Hippocampus/metabolism , gamma-Aminobutyric Acid/metabolism , Animals , Animals, Newborn , Calcium-Calmodulin-Dependent Protein Kinase Type 2/metabolism , Cell Adhesion Molecules, Neuronal/metabolism , Cerebral Cortex/drug effects , Cyclic AMP-Dependent Protein Kinases/metabolism , Cytoplasm/drug effects , Cytoplasm/metabolism , Dopamine/metabolism , Extracellular Matrix Proteins/metabolism , GABA Agents/pharmacology , Hippocampus/drug effects , Mice , Mice, Inbred BALB C , Nerve Tissue Proteins/metabolism , Norepinephrine/metabolism , Receptors, AMPA/metabolism , Receptors, N-Methyl-D-Aspartate/metabolism , Reelin Protein , Serine Endopeptidases/metabolism , Social Behavior , Vigabatrin/pharmacology
2.
Neuropsychopharmacology ; 36(8): 1714-28, 2011 Jul.
Article in English | MEDLINE | ID: mdl-21490592

ABSTRACT

The enzyme methylenetetrahydrofolate reductase (MTHFR) is a part of the homocysteine and folate metabolic pathways, affecting the methylations of DNA, RNA, and proteins. Mthfr deficiency was reported as a risk factor for neurodevelopmental disorders such as autism spectrum disorder and schizophrenia. Neonatal disruption of the GABAergic system is also associated with behavioral outcomes. The interaction between the epigenetic influence of Mthfr deficiency and neonatal exposure to the GABA potentiating drug vigabatrin (GVG) in mice has been shown to have gender-dependent effects on mice anxiety and to have memory impairment effects in a gender-independent manner. Here we show that Mthfr deficiency interacts with neonatal GABA potentiation to alter social behavior in female, but not male, mice. This impairment was associated with a gender-dependent enhancement of proteins implicated in excitatory synapse plasticity in the female cortex. Reelin and fragile X mental retardation 1 protein (FMRP) levels and membrane GluR1/GluR2 ratios were elevated in wild-type mice treated neonatally with GVG and in Mthfr+/- mice treated with saline, but not in Mthfr+/- mice treated with GVG, compared with control groups (wild type treated with saline). A minor influence on the levels of these proteins was observed in male mice cortices, possibly due to high basal protein levels. Interaction between gender, genotype, and treatment was also observed in the GABA pathway. In female mice, GABA Aα2/gephyrin ratios were suppressed in all test groups; in male mice, a genotype-specific enhancement of GABA Aα2/gephyrin was observed. The lack of an effect on either reln or Fmr1 transcription suggests post-transcriptional regulation of these genes. Taken together, these findings suggest that Mthfr deficiency may interact with neonatal GABA potentiation in a gender-dependent manner to interrupt synaptic function. This may illustrate a possible mechanism for the epigenetic involvement of Mthfr deficiency in neurodevelopmental disorders.


Subject(s)
Cerebral Cortex/metabolism , Methylenetetrahydrofolate Reductase (NADPH2)/deficiency , Methylenetetrahydrofolate Reductase (NADPH2)/genetics , Nerve Tissue Proteins/metabolism , Sex Characteristics , Vigabatrin/pharmacology , Animals , Cerebral Cortex/drug effects , Female , Genotype , Male , Mice , Mice, Inbred BALB C , Mice, Mutant Strains , Nerve Tissue Proteins/genetics , Neuronal Plasticity/physiology , Protein Binding/physiology , Random Allocation , Reelin Protein , Synaptic Membranes/genetics , Synaptic Membranes/metabolism , Vigabatrin/metabolism
3.
Behav Brain Res ; 216(2): 505-13, 2011 Jan 20.
Article in English | MEDLINE | ID: mdl-20813139

ABSTRACT

The methylenetetrahydrofolate reductase (Mthfr) gene and/or abnormal homocysteine-folate metabolism are associated with increased risk for birth defects and neuropsychiatric diseases. In addition, disturbances of the GABAergic system in the brain as well as Mthfr polymorphism are associated with neurodevelopmental disorders such as schizophrenia and autism. In the present study we performed behavioral phenotyping of male and female Mthfr mice (wild type and their heterozygous littermates). The present study addresses two main questions: (1) genetic susceptibility, as examined by effects of Mthfr deficiency on behavior (Experiment 1) and (2) possible gene-drug interactions as expressed by behavioral phenotyping of Mthfr-deficient mice neonatally exposed to the GABA potentiating drug GVG (Experiment 2). Newborn development was slightly influenced by Mthfr genotype per se (Experiment 1); however the gene-drug interaction similarly affected reflex development in both male and female offspring (Experiment 2). Hyperactivity was demonstrated in Mthfr heterozygous male mice (Experiment 1) and due to GVG treatment in both Wt and Mthfr+/- male and female mice (Experiment 2). The gene-environment interaction did not affect anxiety-related behavior of male mice (Experiment 2). In female mice, gene-treatment interactions abolished the reduced anxiety observed due to GVG treatment and Mthfr genotype (Experiment 2). Finally, recognition memory of adult mice was impaired due to genotype, treatment and the gene-treatment combination in a sex-independent manner (Experiment 2). Overall, Mthfr deficiency and/or GABA potentiation differentially affect a spectrum of behaviors in male and female mice. This study is the first to describe behavioral phenotypes due to Mthfr genotype, GVG treatment and the interaction between these two factors. The behavioral outcomes suggest that Mthfr deficiency modulates the effects of GABA potentiating drugs. These findings suggest that future treatment strategies should consider a combination of genotyping with drug regimens.


Subject(s)
Behavior, Animal/physiology , GABA Agents/pharmacology , Receptors, GABA/drug effects , Vigabatrin/pharmacology , Analysis of Variance , Animals , Animals, Newborn/genetics , Animals, Newborn/metabolism , Avoidance Learning/drug effects , Avoidance Learning/physiology , Behavior, Animal/drug effects , Exploratory Behavior/drug effects , Exploratory Behavior/physiology , Female , Folic Acid/metabolism , Heterozygote , Homocysteine/metabolism , Homocystinuria/genetics , Homocystinuria/metabolism , Linear Models , Male , Methylenetetrahydrofolate Reductase (NADPH2)/deficiency , Methylenetetrahydrofolate Reductase (NADPH2)/genetics , Methylenetetrahydrofolate Reductase (NADPH2)/metabolism , Mice , Muscle Spasticity/genetics , Muscle Spasticity/metabolism , Phenotype , Psychotic Disorders/genetics , Psychotic Disorders/metabolism , Recognition, Psychology/drug effects , Recognition, Psychology/physiology , Reflex/drug effects , Reflex/genetics , Sex Factors , Statistics, Nonparametric
4.
Neuropsychopharmacology ; 35(5): 1138-54, 2010 Apr.
Article in English | MEDLINE | ID: mdl-20043003

ABSTRACT

Neurodevelopmental disorders, such as schizophrenia and autism, have been associated with disturbances of the GABAergic system in the brain. We examined immediate and long-lasting influences of exposure to the GABA-potentiating drug vigabatrin (GVG) on the GABAergic system in the hippocampus and cerebral cortex, before and during the developmental switch in GABA function (postnatal days P1-7 and P4-14). GVG induced a transient elevation of GABA levels. A feedback response to GABA enhancement was evident by a short-term decrease in glutamate decarboxylase (GAD) 65 and 67 levels. However, the number of GAD65/67-immunoreactive (IR) cells was greater in 2-week-old GVG-treated mice. A long-term increase in GAD65 and GAD67 levels was dependent on brain region and treatment period. Vesicular GABA transporter was insensitive to GVG. The overall effect of GVG on the Cl(-) co-transporters NKCC1 and KCC2 was an enhancement of their synthesis, which was dependent on the treatment period and brain region studied. In addition, a short-term increase was followed by a long-term decrease in KCC2 oligomerization in the cell membrane of P4-14 hippocampi and cerebral cortices. Analysis of the Ca(2+) binding proteins expressed in subpopulations of GABAergic cells, parvalbumin and calbindin, showed region-specific effects of GVG during P4-14 on parvalbumin-IR cell density. Moreover, calbindin levels were elevated in GVG mice compared to controls during this period. Cumulatively, these results suggest a particular susceptibility of the hippocampus to GVG when exposed during days P4-14. In conclusion, our studies have identified modifications of key components in the inhibitory system during a critical developmental period. These findings provide novel insights into the deleterious consequences observed in children following prenatal and neonatal exposure to GABA-potentiating drugs.


Subject(s)
Cerebral Cortex/drug effects , GABA Agents/pharmacology , Hippocampus/drug effects , Vigabatrin/pharmacology , gamma-Aminobutyric Acid/metabolism , Animals , Animals, Newborn , Calbindins , Cell Count , Cell Membrane/drug effects , Cell Membrane/metabolism , Cerebral Cortex/growth & development , Cerebral Cortex/metabolism , Glutamate Decarboxylase/metabolism , Hippocampus/growth & development , Hippocampus/metabolism , Mice , Mice, Inbred BALB C , Parvalbumins/metabolism , Random Allocation , S100 Calcium Binding Protein G/metabolism , Sodium-Potassium-Chloride Symporters/metabolism , Solute Carrier Family 12, Member 2 , Symporters/metabolism , Time Factors , Vesicular Inhibitory Amino Acid Transport Proteins/metabolism , K Cl- Cotransporters
SELECTION OF CITATIONS
SEARCH DETAIL
...